Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$11.06 -1.8%	$8.88	$4.93 ▼ $14.44	$944.75M	0.72	1.19 million shs	583,128 shs
IMMP Prima BioMed	$1.69 +3.0%	$1.78	$1.32 ▼ $2.72	$246.81M	1.71	158,462 shs	82,618 shs
MLYS Mineralys Therapeutics	$14.34 +0.1%	$14.91	$8.24 ▼ $18.38	$934.68M	-0.3	560,265 shs	1.02 million shs
VERV Verve Therapeutics	$10.95 -0.6%	$7.69	$2.86 ▼ $11.41	$976.12M	2.23	2.49 million shs	5.61 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	+3.59%	+4.65%	+30.78%	+25.81%	+93.14%
IMMP Prima BioMed	+0.61%	-2.96%	-4.09%	+6.49%	-19.21%
MLYS Mineralys Therapeutics	-2.05%	-0.35%	+6.47%	+7.27%	-1.78%
VERV Verve Therapeutics	0.00%	-0.63%	+75.76%	+140.09%	+40.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.9247 of 5 stars	3.7	1.0	4.7	2.5	0.8	0.6
IMMP Prima BioMed	1.526 of 5 stars	3.5	1.0	0.0	3.3	0.0	0.0
MLYS Mineralys Therapeutics	2.1958 of 5 stars	3.4	1.0	0.0	1.9	4.2	0.0
VERV Verve Therapeutics	2.8847 of 5 stars	4.2	3.0	0.0	1.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	297.83% Upside
IMMP Prima BioMed	3.00	Buy	$7.00	314.20% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	124.90% Upside
VERV Verve Therapeutics	2.33	Hold	$14.57	33.07% Upside

Current Analyst Ratings Breakdown

Latest IMMP, VERV, AVXL, and MLYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$20.00 ➝ $13.50
6/26/2025	VERV Verve Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/18/2025	VERV Verve Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$28.00 ➝ $11.00
6/18/2025	VERV Verve Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00
6/18/2025	VERV Verve Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$13.50
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/17/2025	VERV Verve Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Market Perform
6/17/2025	VERV Verve Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$39.00 ➝ $13.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
IMMP Prima BioMed	$5.14M	48.02	N/A	N/A	$1.05 per share	1.61
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
VERV Verve Therapeutics	$59.61M	16.37	N/A	N/A	$5.83 per share	1.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-40.93%	-36.38%	8/5/2025 (Estimated)
IMMP Prima BioMed	-$28.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
VERV Verve Therapeutics	-$198.71M	-$2.11	N/A	N/A	N/A	-303.64%	-35.81%	-27.57%	8/14/2025 (Estimated)

Latest IMMP, VERV, AVXL, and MLYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VERV Verve Therapeutics	-$0.70	N/A	N/A	N/A	$4.26 million	N/A
8/12/2025	Q2 2025	MLYS Mineralys Therapeutics	-$0.78	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q3 2025	AVXL Anavex Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	VERV Verve Therapeutics	-$0.71	-$0.35	+$0.36	-$0.35	$7.13 million	$32.98 million
5/13/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	-$0.13	+$0.03	-$0.13	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
VERV Verve Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	6.74	6.74
IMMP Prima BioMed	N/A	18.86	N/A
MLYS Mineralys Therapeutics	N/A	26.48	26.48
VERV Verve Therapeutics	N/A	9.84	9.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
IMMP Prima BioMed	2.32%
MLYS Mineralys Therapeutics	84.46%
VERV Verve Therapeutics	97.11%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.40%
IMMP Prima BioMed	3.07%
MLYS Mineralys Therapeutics	25.56%
VERV Verve Therapeutics	19.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.42 million	75.64 million	Optionable
IMMP Prima BioMed	2,021	146.04 million	141.56 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
VERV Verve Therapeutics	110	89.14 million	71.40 million	Optionable

IMMP, VERV, AVXL, and MLYS Headlines

Recent News About These Companies

Lilly’s $1 billion CRISPR bet: what Verve means for gene editing

July 16 at 7:41 PM | thepharmaletter.comT

Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook (VERV)

...

July 15 at 4:27 PM | marketbeat.com

Biotech Stocks Are Ready to Rebound. Gilead Sciences and 2 More to Watch Now.

July 14 at 12:44 PM | msn.com

Biotech Stocks Are Ready to Rebound. 3 to Watch Now.

July 14 at 2:41 AM | msn.com

Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.

July 13, 2025 | hindustantimes.comH

Experimental treatment for high cholesterol edits DNA in the body to reduce LDL

July 11, 2025 | msn.com

Verve Therapeutics Inc News (VERV) - Investing.com

July 4, 2025 | investing.com

Verve Therapeutics, Inc. (NASDAQ:VERV) Given Average Recommendation of "Hold" by Analysts

July 3, 2025 | marketbeat.com

June’s Busy Buyout Binge Bolsters M&A Stats for H1

July 1, 2025 | biospace.comB

BMO Capital Markets Downgrades Verve Therapeutics (NASDAQ:VERV) to Hold

June 28, 2025 | marketbeat.com

BMO Capital Markets Reiterates Market Perform Rating for Verve Therapeutics (NASDAQ:VERV)

June 27, 2025 | marketbeat.com

VERV Verve Therapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Eli Lilly's Strategic Acquisition of Verve Therapeutics

June 24, 2025 | pharmiweb.comP

GAMMA Investing LLC Acquires 27,485 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

June 24, 2025 | marketbeat.com

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

June 23, 2025 | insidermonkey.com

Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

June 20, 2025 | fool.com

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Verve Therapeutics, Inc. (NASDAQ: VERV)

June 20, 2025 | globenewswire.com

Q2 Earnings Forecast for VERV Issued By Lifesci Capital

June 19, 2025 | marketbeat.com

Eli Lilly to Buy Gene Therapy Firm Verve in $1 Billion Deal to Develop Heart Drug

June 19, 2025 | insidenova.comI

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

June 19, 2025 | msn.com

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

June 18, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP, VERV, AVXL, and MLYS Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$11.06 -0.20 (-1.78%)

Closing price 04:00 PM Eastern

Extended Trading

$11.16 +0.10 (+0.95%)

As of 07:33 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Prima BioMed NASDAQ:IMMP

$1.69 +0.05 (+3.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.69 0.00 (0.00%)

As of 06:51 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Mineralys Therapeutics NASDAQ:MLYS

$14.34 +0.02 (+0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$14.70 +0.37 (+2.55%)

As of 06:52 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Verve Therapeutics NASDAQ:VERV

$10.95 -0.07 (-0.64%)

Closing price 04:00 PM Eastern

Extended Trading

$10.98 +0.03 (+0.23%)

As of 07:05 PM Eastern

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time